Nov 12, 2019 / 10:00PM GMT
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
My name is Evan Seigerman, I'm the senior large cap biotechnology analyst here at Crédit Suisse, and it's my pleasure to introduce Theravance Biopharma with the Chairman and CEO, Rick Winningham.
Rick E. Winningham - Theravance Biopharma, Inc. - Chairman & CEO
Thank you, and I'd like to thank Crédit Suisse for inviting us here to present. For the next few minutes, I'll be giving you an update on Theravance Biopharma. First, the obligatory safe harbor statement, and forward looking statements that I'll be making throughout the course of my presentation. We're in a very exciting period in history of the company. By, really, the fruits of the labor over the last several years, we've been able to build a significant pipeline of products, from products that are on the market, products that are in Phase III, Phase II, entering the clinic in Phase I and then a fairly deep research pipeline.
Some of the key programs that I'll be
Theravance Biopharma Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers